Video: Who Am I?| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: hospital

Methotrexate Halt Feasible in Some Etanercept RA Responders

David Douglas  |  September 21, 2015

NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:combination therapyetanerceptMethotrexateRheumatoid Arthritis (RA)

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

Michele B. Kaufman, PharmD, BCGP  |  September 16, 2015

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:combination therapyFDAFood and Drug AdministrationGolimumabInjectionMental HealthMethotrexateOsteoporosispostmenopauseromosozumab

Figure 1: Hematoxylin & Eosin Staining

Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report

Paul Hoover, MD, PhD, & Lindsey MacFarlane, MD  |  September 15, 2015

A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:ClinicalDiagnosiskidneyoutcomepatient careSLEstemic lupus erythematosus

Rheumatologists on the Move, September 2015

Ann-Marie Lindstrom  |  September 15, 2015

Teresa Fama: Rheumatologist to Chair Public Advisory Council Teresa Fama, MD, is the new chair of the New England Comparative Effectiveness Public Advisory Council (CEPAC). A rheumatologist who practices in Berlin, Vt., Dr. Fama has previous experience in public policy, specifically health policy. Before she began her second career as a physician, Dr. Fama was…

Filed under:Career DevelopmentProfessional TopicsProfiles Tagged with:appointmentsAwardsCareerrheumatologist

Vitamin D in Rheumatology: Cause and Effect Unclear

Vanessa Caceres  |  September 15, 2015

The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…

Filed under:ConditionsOsteoarthritis and Bone Disorders Tagged with:ClinicalOsteoporosisOutcomespatient carerheumatologyTreatmentVitamin D

Preparing Immunocompromised Patients for Risks of Traveling Abroad

Susan Bernstein  |  September 15, 2015

Summer is a season for travel, so if your immunocompromised patients plan to journey to regions where there are outbreaks of infections, such as chikungunya, tuberculosis, typhoid, yellow fever or other diseases, communication and preparation may prevent serious health events. “The world teems with disease-causing organisms, and almost every infection is more serious in the…

Filed under:Conditions Tagged with:ClinicalDiseaseoutbreakspatient carerheumatologistsrisk

Fellow’s Forum Case Report: Limited Cutaneous Systemic Sclerosis

Eunjung Kim, MD, Hyun Bae, MD, Ritu Kathuria, MD, Alexandra Gottdiener, MD, & Girish Sonpal, MD, FACR  |  September 15, 2015

Systemic sclerosis (SSc) is an acquired, sporadic, autoimmune, connective tissue disease with two subsets: limited cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma (dcSSc). In the U.S., the annual incidence is about 20 cases per 1 million adults, with a prevalence of about 240 cases per 1 million adults.1 As with other connective tissue disorders, SSc…

Filed under:ConditionsSystemic Sclerosis Tagged with:Clinicalpatient carerheumatologistSystemic sclerosis

Cardiovascular Risk in Tocilizumab Therapy for RA

Kathy Holliman  |  September 15, 2015

Observation and research have confirmed that patients with rheumatoid arthritis (RA) are at greater risk of cardiovascular disease than their peers of similar age and gender, and that traditional risk factors and chronic inflammation associated with RA apparently play a significant role in that risk. However, predicting which patients with rheumatoid arthritis are at greater…

Filed under:ConditionsRheumatoid Arthritis Tagged with:Cardiovascular diseasepatient careRheumatoid arthritisrisktocilizumabTreatment

Guselkumab Studied to Treat RA, Plaque Psoriasis

Michele B. Kaufman, PharmD, BCGP  |  September 15, 2015

Guselkumab Studied to Treat RA & Plaque Psoriasis Guselkumab (GUS) is a subcutaneously administered monoclonal antibody that targets interleukin (IL) 23.1 It is being investigated in a Phase 2 study to treat rheumatoid arthritis (RA) and moderate to severe plaque psoriasis (PsA). On June 11, 2015, at the 2015 meeting of the European League Against…

Filed under:Biologics/DMARDsConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Biosimilarsclinical trialsDrugsguselkumaboutcomeplaque psoriasisRheumatoid arthritisrheumatologySafety

EULAR 2015: Emerging Concepts, Treatments for Axial Spondyloarthritis

Thomas R. Collins  |  September 15, 2015

ROME, Italy—When it comes to thinking about disease modification—a main goal in the treatment of axial spondyloarthritis (axial SpA) and other inflammatory diseases—it’s time to reconsider the concept, an expert said at EULAR 2015, the annual congress of the European League Against Rheumatism (EULAR). The traditional way of assessing disease modification, inhibiting radiographic progression, is…

Filed under:Axial SpondyloarthritisConditionsMeeting Reports Tagged with:patient careTreatment

  • « Previous Page
  • 1
  • …
  • 234
  • 235
  • 236
  • 237
  • 238
  • …
  • 326
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences